阿司匹林对健康老年人心血管事件与出血的影响
ASPREE试验在澳大利亚和美国纳入19114名无心血管病、痴呆或失能的社区居住老年人(≥70岁,美国黑人和西班牙裔≥65岁),随机接受100 mg肠溶阿司匹林或安慰剂。中位随访4.7年,心血管病发生率为阿司匹林组10.7/1000人年 vs 安慰剂组11.3/1000人年(HR 0.95;95%CI 0.83–1.08),无显著差异。大出血发生率为8.6/1000人年 vs 6.2/1000人年(HR 1.38;95%CI 1.18–1.62;P<0.001),阿司匹林组显著升高。结论:老年人低剂量阿司匹林一级预防未显著降低心血管病风险,反而显著增加大出血风险。
要点
- 社区健康老年人(≥70岁,美国黑人和西班牙裔≥65岁)每日100 mg肠溶阿司匹林一级预防,大出血发生率8.6/1000人年 vs 安慰剂6.2/1000人年(HR 1.38;95%CI 1.18–1.62;P<0.001)。
- 心血管病发生率为阿司匹林组10.7/1000人年 vs 安慰剂组11.3/1000人年(HR 0.95;95%CI 0.83–1.08),差异未达统计学显著。
- 中位随访4.7年,共纳入19114人(阿司匹林9525人、安慰剂9589人),人群为无心血管病、痴呆或失能的社区居住老年人。
- ASPREE结论:老年人低剂量阿司匹林一级预防导致大出血风险显著升高,未显著降低心血管病风险。
适用人群与场景
- 澳大利亚和美国的社区居住老年人,年龄≥70岁,或美国黑人和西班牙裔≥65岁。
- 纳入者无心血管病、痴呆或失能。
处置流程与药物剂量
- 随机接受100 mg肠溶阿司匹林或安慰剂,每日口服(原文未写明服法频次,原文仅写随机接受100 mg肠溶阿司匹林或安慰剂)。
研究设计与关键结果
- 研究类型:随机对照试验;样本量19114人,阿司匹林组9525人、安慰剂组9589人;人群为澳大利亚和美国社区居住老年人;干预为100 mg肠溶阿司匹林 vs 安慰剂;中位随访4.7年。
- 主要终点为死亡、痴呆或持续躯体失能的复合终点,结果另文报告。
- 心血管病(定义为致死性冠心病、非致死性心肌梗死、致死性或非致死性卒中、或因心力衰竭住院)发生率:阿司匹林组10.7/1000人年 vs 安慰剂组11.3/1000人年(HR 0.95;95%CI 0.83–1.08)。
- 大出血发生率:阿司匹林组8.6/1000人年 vs 安慰剂组6.2/1000人年(HR 1.38;95%CI 1.18–1.62;P<0.001)。
证据类型、等级与局限
- 证据类型:随机对照试验(ASPREE,ClinicalTrials.gov NCT01038583),由美国国家老龄化研究所等资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:老年人低剂量阿司匹林一级预防导致大出血风险显著升高,未显著降低心血管病风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk.
METHODS: From 2010 through 2014, we enrolled community-dwelling men and women in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. The primary end point was a composite of death, dementia, or persistent physical disability; results for this end point are reported in another article in the Journal. Secondary end points included major hemorrhage and cardiovascular disease (defined as fatal coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure).
RESULTS: Of the 19,114 persons who were enrolled in the trial, 9525 were assigned to receive aspirin and 9589 to receive placebo. After a median of 4.7 years of follow-up, the rate of cardiovascular disease was 10.7 events per 1000 person-years in the aspirin group and 11.3 events per 1000 person-years in the placebo group (hazard ratio, 0.95; 95% confidence interval [CI], 0.83 to 1.08). The rate of major hemorrhage was 8.6 events per 1000 person-years and 6.2 events per 1000 person-years, respectively (hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001).
CONCLUSIONS: The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583 .).
参考来源
- McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018. PMID: 30221597. doi:10.1056/NEJMoa1805819
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。